Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
298.21B
Market cap298.21B
Price-Earnings ratio
33.52
Price-Earnings ratio33.52
Dividend yield
2.79%
Dividend yield2.79%
Average volume
11.60M
Average volume11.60M
High today
$122.71
High today$122.71
Low today
$118.91
Low today$118.91
Open price
$120.04
Open price$120.04
Volume
13.04M
Volume13.04M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$76.66
52 Week low$76.66

Stock Snapshot

With a market cap of 298.21B, Merck(MRK) trades at $120.53. The stock has a price-to-earnings ratio of 33.52 and currently yields dividends of 2.8%.

As of 2026-06-11, Merck(MRK) stock has fluctuated between $118.91 and $122.71. The current price stands at $120.53, placing the stock +1.4% above today's low and -1.8% off the high.

The Merck(MRK)'s current trading volume is 13.04M, compared to an average daily volume of 11.6M.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $76.66.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $76.66.

MRK News

Nasdaq 7h
Investors Heavily Search Merck & Co., Inc.: Here is What You Need to Know

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influenc...

Investors Heavily Search Merck & Co., Inc.: Here is What You Need to Know
Investing.com 9h
Merck Animal Health to acquire poultry tech firm TARGAN - Investing.com

...

Merck Animal Health to acquire poultry tech firm TARGAN - Investing.com
Nasdaq 9h
Merck Animal Health To Acquire TARGAN To Expand Poultry Technology Portfolio

(RTTNews) - Merck Animal Health, a division of Merck & Co. (MRK), on Thursday announced a definitive agreement to acquire TARGAN, a privately held developer of...

Merck Animal Health To Acquire TARGAN To Expand Poultry Technology Portfolio

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More MRK News

TipRanks 9h
Merck Animal Health to acquire Targan

Merck (MRK) division Merck Animal Health has signed a definitive agreement to acquire Targan, a privately held innovator in developing and commercializing biode...

Simply Wall St 13h
Assessing Merck Valuation After Recent Trading Dip And Oncology Pipeline Expectations

Advertisement Merck stock snapshot after recent trading move Merck (MRK) moved slightly lower in the latest trading session, with the stock closing at US$119....

Assessing Merck Valuation After Recent Trading Dip And Oncology Pipeline Expectations
Zacks 24h
Top Research Reports for Merck, Southern Company & Lumentum

Wednesday, June 10, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports...

Top Research Reports for Merck, Southern Company & Lumentum
Benzinga 2d
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

While the combo showed a numerical improvement in progression-free survival, it did not reach statistical significance, and investigators said the probability o...

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
TipRanks 3d
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study

Merck (MRK) and Gilead Sciences (GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy in combination wi...

24/7 Wall St. 4d
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech By Thomas Richmond Published Jun 7, 9:30AM EDT Quick Read Merck's Keytr...

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
Simply Wall St 7d
Calderasib–Keytruda Breakthrough Therapy Status Might Change The Case For Investing In Merck

In late May 2026, Merck reported that its investigational KRAS G12C inhibitor calderasib (MK-1084), when combined with KEYTRUDA, received FDA Breakthrough Thera...

Calderasib–Keytruda Breakthrough Therapy Status Might Change The Case For Investing In Merck

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.